Literature DB >> 7589879

Insulin increases cyclic nucleotide content in human vascular smooth muscle cells: a mechanism potentially involved in insulin-induced modulation of vascular tone.

M Trovati1, P Massucco, L Mattiello, F Cavalot, E Mularoni, A Hahn, G Anfossi.   

Abstract

It has been suggested that insulin exerts a vasodilating effect, but the mechanisms involved are not completely understood. Since cyclic nucleotides mediate the vasodilation induced by endogenous substances, such as prostacyclin and nitric oxide, we aimed to investigate the influence of insulin (concentration range 240-960 pmol/l) on both cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) content in human vascular smooth muscle cells. Insulin dose-dependently increased both nucleotides (cAMP: from 0.7 +/- 0.1 to 2.6 +/- 0.4 pmol/10(6) cells, p = 0.0001; cGMP: from 1.3 +/- 0.2 to 3.4 +/- 0.7 pmol/10(6) cells, p = 0.033). This increase is receptor-mediated, since it was blunted when cells were preincubated with the tyrosine kinase inhibitor genistein. The effect of insulin remained significant (p = 0.0001) when preincubation with the phosphodiesterase inhibitor theophylline prevented cyclic nucleotide catabolism. The increase of cGMP was blunted when the cells were preincubated with the guanylate cyclase inhibitor methylene blue, and with the nitric oxide-synthase inhibitor NG-monomethyl-L-arginine. At all the concentrations tested, insulin potentiated the increase of cAMP induced by the stable prostacyclin analogue Iloprost (p = 0.0001), whereas only at 1920 pmol/l did it potentiate the cGMP increase induced by glyceryltrinitrate (p = 0.05). This study demonstrates that the vasodilating effects exerted by insulin may at least in part be attributable to an increase of both cGMP and cAMP via a receptor-mediated activation of adenylate and guanylate cyclases in human vascular smooth muscle cells and that the insulin effect on cGMP is mediated by nitric oxide.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7589879     DOI: 10.1007/BF00400582

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  34 in total

1.  Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans.

Authors:  E A Anderson; R P Hoffman; T W Balon; C A Sinkey; A L Mark
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

2.  Insulin influences the renin-angiotensin-aldosterone system in humans.

Authors:  M Trovati; P Massucco; G Anfossi; F Cavalot; E Mularoni; L Mattiello; G Rocca; G Emanuelli
Journal:  Metabolism       Date:  1989-06       Impact factor: 8.694

3.  Effects of lipolytic and antilipolytic substances on adenosine 3',5'-monophosphate levels in isolated fat cells.

Authors:  R W Butcher; C E Baird; E W Sutherland
Journal:  J Biol Chem       Date:  1968-04-25       Impact factor: 5.157

4.  The vasodilator action of insulin. Implications for the insulin hypothesis of hypertension.

Authors:  E A Anderson; A L Mark
Journal:  Hypertension       Date:  1993-02       Impact factor: 10.190

5.  Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans.

Authors:  P Vollenweider; L Tappy; D Randin; P Schneiter; E Jéquier; P Nicod; U Scherrer
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

6.  Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man.

Authors:  J W Rowe; J B Young; K L Minaker; A L Stevens; J Pallotta; L Landsberg
Journal:  Diabetes       Date:  1981-03       Impact factor: 9.461

7.  Insulin attenuates vasoconstriction by noradrenaline, serotonin and potassium chloride in rat mesenteric arterioles.

Authors:  G K Wambach; D Liu
Journal:  Clin Exp Hypertens A       Date:  1992

8.  Human insulin-mediated enhancement of vascular beta-adrenergic responsiveness.

Authors:  R Gros; K R Borkowski; R D Feldman
Journal:  Hypertension       Date:  1994-05       Impact factor: 10.190

9.  Insulin modulates circulating endothelin-1 levels in humans.

Authors:  H A Wolpert; S N Steen; N W Istfan; D C Simonson
Journal:  Metabolism       Date:  1993-08       Impact factor: 8.694

10.  Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo.

Authors:  M Trovati; G Anfossi; F Cavalot; P Massucco; E Mularoni; G Emanuelli
Journal:  Diabetes       Date:  1988-06       Impact factor: 9.461

View more
  5 in total

1.  Phosphorylation of P20 is associated with the actions of insulin in rat skeletal and smooth muscle.

Authors:  Y Wang; A Xu; G J Cooper
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

2.  Are insulin resistance and atherosclerosis the consequences of oxidative stress?

Authors:  I Wittmann; J Nagy
Journal:  Diabetologia       Date:  1996-08       Impact factor: 10.122

3.  Studies on the influence of insulin on cyclic adenosine monophosphate in human vascular smooth muscle cells: dependence on cyclic guanosine monophosphate and modulation of catecholamine effects.

Authors:  M Trovati; P Massucco; L Mattiello; F Cavalot; E M Mularoni; A W Hahn; G Anfossi
Journal:  Diabetologia       Date:  1996-10       Impact factor: 10.122

4.  The vascular effects of L-Arginine in humans. The role of endogenous insulin.

Authors:  D Giugliano; R Marfella; G Verrazzo; R Acampora; L Coppola; D Cozzolino; F D'Onofrio
Journal:  J Clin Invest       Date:  1997-02-01       Impact factor: 14.808

Review 5.  Cardiometabolic syndrome: pathophysiology and treatment.

Authors:  Jonathan P Castro; Fadi A El-Atat; Samy I McFarlane; Ashish Aneja; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2003-10       Impact factor: 5.369

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.